

WEST PHARMACEUTICAL SERVICES INC
Form 8-K
July 01, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported) – June 28, 2011

WEST PHARMACEUTICAL
SERVICES, INC.

(Exact name of registrant as specified in its charter)

Pennsylvania
(State or other jurisdiction
of Incorporation)

1-8036
(Commission File
Number)

23-1210010
(IRS Employer
Identification No.)

101 Gordon Drive, PO Box
645, Lionville, PA
(Address of principal
executive offices)

19341-0645
(Zip Code)

Registrant's telephone number, including area code: 610-594-2900

Not Applicable
(Former name or address, if changed since
last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01. Material Definitive Agreement.

On June 28, 2011, West Pharmaceutical Services, Inc. entered into a Global Supply Agreement with ExxonMobil Chemical Company (“EMCC”). The agreement is effective for the period January 1, 2011 through December 31, 2013.

Under the agreement EMCC and certain of its subsidiaries have agreed to supply certain identified Exxon® (Exxon is a registered trademark of ExxonMobil Corporation) butyl polymers to West and certain of its subsidiaries and affiliates. The EMCC polymers are used as a principal raw material in a broad range of West’s polymer-based pharmaceutical packaging products.

Pricing for the polymers is based on discounts of EMCC’s and its subsidiaries’ list prices. The parties may renegotiate pricing based on changes in certain economic trends and conditions, including but not limited to the levels of industrial production, tire demand, labor rates, energy costs and foreign exchange relationships.

The foregoing summary of the terms of the agreement does not purport to be complete and is qualified in its entirety by reference to the Agreement, which is filed as Exhibit 10.1 to this Report and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

Exhibit 10.1 Global Supply Agreement, entered into on June 28, 2011 and effective from January 1, 2011 through December 31, 2013, between ExxonMobil Chemical Company and us.*

* Certain portions of this exhibit have been omitted pursuant to a confidential treatment request submitted to the SEC.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WEST
PHARMACEUTICAL
SERVICES, INC.

/s/ John R. Gailey III
John R. Gailey III,
Vice President, General
Counsel and Secretary

July 1, 2011

EXHIBIT INDEX

Exhibit No.	Description
Exhibit 10.1	Global Supply Agreement, entered into on June 28, 2011 and effective from January 1, 2011 through December 31, 2013, between ExxonMobil Chemical Company and us. *

*Certain portions of this exhibit have been omitted pursuant to a confidential treatment request submitted to the SEC.

